https://www.onchillespharma.com https://www.onchillespharma.com/science https://www.onchillespharma.com/pipeline https://www.onchillespharma.com/team https://www.onchillespharma.com/newsroom https://www.onchillespharma.com/contact https://www.onchillespharma.com/privacy-policy https://www.onchillespharma.com/terms-of-use https://www.onchillespharma.com/newsroom/onchilles-pharma-to-present-op-neu-101-trial-in-progress-at-esmo-congress-2026 2026-07-21 https://www.onchillespharma.com/newsroom/onchilles-pharma-doses-first-patient-in-phase-1-2-clinical-trial-of-n17350-for-advanced-solid-tumors 2026-06-04 https://www.onchillespharma.com/newsroom/onchilles-pharma-to-present-trial-in-progress-poster-at-the-2026-asco-annual-meeting 2026-04-21 https://www.onchillespharma.com/newsroom/onchilles-pharma-presents-at-aacr-2026-new-preclinical-data-from-the-systemically-delivered-neu-002 2026-04-17 https://www.onchillespharma.com/newsroom/onchilles-pharma-to-present-new-preclinical-data-on-systemically-delivered-neu-002-program-at-aacr-2 2026-03-17 https://www.onchillespharma.com/newsroom/onchilles-pharma-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference 2026-02-24 https://www.onchillespharma.com/newsroom/onchilles-pharma-announces-ind-clearance-for-n17350 2026-02-02 https://www.onchillespharma.com/newsroom/onchilles-pharma-publishes-landmark-elane-pathway-study 2025-11-07 https://www.onchillespharma.com/newsroom/onchilles-pharma-presents-new-data-at-aacr-2025 2025-04-25 https://www.onchillespharma.com/newsroom/onchilles-pharma-to-present-new-preclinical-data-for-n17350-at-aacr-2025 2025-03-25 https://www.onchillespharma.com/newsroom/onchilles-expands-leadership-team 2025-01-14 https://www.onchillespharma.com/newsroom/onchilles-pharma-presents-new-preclinical-data-for-the-systemically-delivered-neu-002-program-target 2024-11-07 https://www.onchillespharma.com/newsroom/onchilles-pharma-announces-presentation-of-data-for-the-neu-002-program-at-sitc-2024 2024-10-04 https://www.onchillespharma.com/newsroom/pharmashots-onchilles-pharma-at-aacr-2024-lev-becker-in-a-stimulating-conversation-with-pharmashot 2024-06-24 https://www.onchillespharma.com/newsroom/sdbj-onchilles-pharma-shares-promising-preclinical-data-new-mechanism-discovered-could-treat-wide 2024-04-23 https://www.onchillespharma.com/newsroom/onchilles-pharma-presents-at-aacr-2024-new-preclinical-data-for-n17350-and-n17465-demonstrating-the 2024-04-09 https://www.onchillespharma.com/newsroom/onchilles-pharma-announces-two-presentations-of-new-preclinical-data-for-n17350-and-n17465-at-aacr-2 2024-03-06 https://www.onchillespharma.com/newsroom/drug-target-review-transforming-cancer-treatment-for-greatest-impact 2024-01-05 https://www.onchillespharma.com/newsroom/onchilles-pharma-presents-at-sitc-2023-new-preclinical-data-for-n17350-a-potential-pan-cancer-thera 2023-11-03 https://www.onchillespharma.com/newsroom/onchilles-pharma-announces-presentation-of-data-for-n17350-program-at-sitc-2023 2023-09-27 https://www.onchillespharma.com/newsroom/onchilles-pharma-presents-at-aacr-2023-new-preclinical-data-on-n17350-a-first-in-class-immuno-oncol 2023-04-19 https://www.onchillespharma.com/newsroom/onchilles-pharma-announces-presentation-of-preclinical-data-for-n17350-at-aacr-2023 2023-03-14 https://www.onchillespharma.com/newsroom/onchilles-pharma-nominates-first-drug-development-candidate-targeting-neutrophil-biology-for-the-tre 2022-12-12